Fig. 1 · Structure

Documents & Downloads

(-)-Blebbistatin

myosin II inhibitor

Blebbistatin, a myosin II inhibitor, is photoinactivated by blue light.

In Stock

Publications for (-)-Blebbistatin

2 publications citing this product

  1. Anastasiia Kovaleva, .et al. , Int J Mol Sci, 2025, Aug 9;26(16):7701 PMID: 40869022
  2. Anastasiia Kovaleva, .et al. , Cell and Developmental Biology, 2024, Dec 25

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Target & Activity

Target Activity Value
non-muscle myosin II ATPases (Cell-free assay) 0.5 μM-5 μM

In Vivo Studies

In a mouse ear-dermatitis model, daily topical (−)-blebbistatin at 5 mg/mL for 20 days did not significantly improve dermatitis score or ear-thickness change versus vehicle. Positive findings for the separately tested O-benzoate derivative should not be attributed to the parent compound. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Parent (−)-blebbistatin in a mouse dermatitis model

Animal study · Female NC/Nga mice, 8 weeks old at acquisition, with mite-antigen-induced ear dermatitis; n = 8 per group [1]

Daily topical parent (−)-blebbistatin showed a downward trend in dermatitis score without a statistically significant difference from vehicle. Ear-thickness change was also not significantly different from vehicle. Body-weight change was not affected by drug administration. The significant improvements reported for the O-benzoate derivative are not assigned to the parent.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Dermatitis scoreComparison with vehicle Downward trend; no statistically significant difference[1]
Change in ear thicknessComparison with vehicle No statistically significant difference[1]

Conditions shared by the study groups

Route
Topical to ear lesion
Frequency
Daily (Figure 1A)
Treatment course
20 days from Day 15; endpoint on Day 35
Vehicle
Acetone/methanol
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Parent (−)-blebbistatin
5 mg/mL (0.5% label in Figure 1)
Vehicle group; separate 0.1% FK506 positive-control group; n = 8/groupDermatitis score and ear-thickness change were not significantly different from vehicle; body-weight change was unaffected.[1]
Parent (−)-blebbistatin
Model: Female NC/Nga mice with established ear dermatitis; n = 8
Reported limits: Topical volume and solvent ratio not specified in the retrieved treatment paragraph.
Methods and source locations

Compound reported in the paper: (−)-Blebbistatin; Compound label in the paper: 0.5% (−)-blebbistatin arm in Figure 1

Model-specific negative parent-compound result; no evidence of established dermatitis efficacy.

Materials and methods: Animals; House dust mite-induced AD model; Results: Topical administration of (S)-(-)-blebbistatin O-benzoate reduces dermatitis symptoms in NC/Nga mice; Figure 1A–D

Dermatitis score: Serial four-component macroscopic dermatitis scoring; n = 8 mice/group. Figure 1 data are mean ± SE. In-vivo comparisons used Steel’s test or the Brunner–Munzel test; the exact test for this endpoint is not assigned in the retrieved methods. — First Results subsection; Figure 1B and caption

Change in ear thickness: Upright-gauge measurements of auricular thickness, expressed as change from the grouping-day value; n = 8 mice/group. Figure 1 data are mean ± SE. — First Results subsection; Figure 1C and caption

Parent (−)-blebbistatin · Materials and methods: Animals; House dust mite-induced AD model; Results: Topical administration of (S)-(-)-blebbistatin O-benzoate reduces dermatitis symptoms in NC/Nga mice; Figure 1A–D

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 856925-71-8
Applications myosin II inhibitor
Formula C18H16N2O2
Molecular Weight 292.33
Synonyms (S)-Blebbistatin
SMILES
CC1=CC2=C(C=C1)N=C3[C@](C2=O)(CCN3C4=CC=CC=C4)O

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 55 mg/mL (188.14 mM)
Water Insoluble
Ethanol Insoluble

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

In Vivo Preparation

Concentration
4 mg/mL
Vehicle
2% DMSO+40% PEG 300+5% Tween 80+ddH2O

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Research References

  1. [1] Sahara S, Ueno A, Wakita N, et al. (S)-(-)-blebbistatin O-benzoate has the potential to improve atopic dermatitis symptoms in NC/Nga mice by upregulating epidermal barrier function and inhibiting type 2 alarmin cytokine induction PloS one (2024). PMID: 38713650 DOI: 10.1371/journal.pone.0302781 Source material

Publications

2 publications citing this product

  1. Anastasiia Kovaleva, .et al. , Int J Mol Sci, 2025, Aug 9;26(16):7701 PMID: 40869022
  2. Anastasiia Kovaleva, .et al. , Cell and Developmental Biology, 2024, Dec 25

Added to your cart

View Cart Checkout
Loading...